Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CHTR1D
The experimentally established mechanism targets of Ergotamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | HTR6 | P50406 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergotamine SCHEMBL783018 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29420131 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL22171508 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL18134607 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL783017 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL453882 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29567350 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL11086376 | 0.99 | CYP3A4 (0.99) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL28990226 | 0.99 | CYP3A4 (0.99) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL22231343 | 0.99 | CYP3A4 (0.99) | CYP3A4DRD2HTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21076 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2026043908-A1 | COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS | ALLTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| US-20250381175-A1 | COMPOUNDS FOR INCREASING NEURAL PLASTICITY | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| WO-2025202418-A1 | METHODS AND COMPOSITIONS | VRG 145 ZRT. (HU) | 2025-10-02 | — | — | WO | claimed |
| US-20250302802-A1 | METHODS AND COMPOSITIONS | VRG 145 ZRT (HU) | 2025-10-02 | — | — | US | claimed |
| EP-0114563-A1 | Cytostatically effective combination | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-08-01 | — | — | EP | claimed |
| EP-0092200-A2 | Resorbable sheet for closing and healing wounds, and process for its production | Serapharm GmbH & Co. KG (DE) | 1983-10-26 | — | — | EP | claimed |
| EP-0022418-B1 | PROCESS FOR THE PREPARATION OF ERGOTAMINE AND OF ALCALOIDS OF THE ERGOTOXINE GROUP | PIERRE FABRE S.A. (FR) | 1983-05-11 | — | — | EP | claimed |
| US-4380534-A | WAXES, STEROIDS, ALKALOIDS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1983-04-19 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4315937-A | Ergots and their use in treating minimal brain dysfunction | SANDOZ LTD. (CH) | 1982-02-16 | — | — | US | claimed |
| US-4220636-A | MIGRAINE TREATMENT, ALKALI OR ALKALINE EARTH SALT OF SULFUROUS OR PYROSULFURIC ACID OR THEIR ALDEHYDE OR KETONE ADDITION PRODUCTS | Deutsche Gesellschaft fuer Unwelt-Schutz e. V. (DE) | 1980-09-02 | — | — | US | claimed |
| US-4078065-A | ERGOT ALKALOID, ETHOXYLATED CHOLESTERIN FOR TREATMENT OF MIGRAINES OR HYPERTENSION | SANDOZ LTD. (CH) | 1978-03-07 | — | — | US | claimed |
| US-4012498-A | Sustained release tablet formulations | SANDOZ, INC. (US) | 1977-03-15 | — | — | US | claimed |
| US-3934580-A | Chemically acting intra-uterine device | APAMED ANSTALT (FL) | 1976-01-27 | — | — | US | claimed |